Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes

Diabetes Care. 2005 Dec;28(12):2980-1. doi: 10.2337/diacare.28.12.2980-a.

Authors

Toshihide Kawai¹, Mikiya Tokui, Osamu Funae, Shu Meguro, Satoru Yamada, Mitsuhisa Tabata, Akira Shimada

Affiliation

¹ Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. tkawai@sc.itc.keio.ac.jp

PMID: 16306567
DOI: 10.2337/diacare.28.12.2980-a

No abstract available

Publication types

Controlled Clinical Trial

MeSH terms

Aged
Blood Glucose / metabolism*
Diabetes Mellitus, Type 2 / blood*
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Lipids / blood*
Male
Middle Aged
Quinolines / therapeutic use*

Substances

Blood Glucose
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Quinolines
pitavastatin